International Mixed Unit ‘Inflammation and Leishmania infection’ (IMU-InflaLeish): Exploiting host-pathogen interaction for the discovery of novel anti-microbial drug targets and drug candidates.
Recipient: Gerald Spaeth, PI Agency: Pasteur Institute, Type: Collaborative grant, 01/2016 – 12/2019 Based on ongoing collaborative actions we propose the creation of an IMU between three teams at IP Paris (G. Spaeth), IP […]
PTR 496 – Investigating the reciprocal relationship between macrophage inflammasome activity and intracellular Leishmania infection
Our proposal aims to decipher novel subversion strategies used by Leishmania (i) to withstand, circumvent or inhibit anti-microbial activities of host macrophages and (ii) to interfere with the induction of Leishmania-specific immune responses. We […]
FP7 Targeting the Leishmania kinome for the development of novel anti-parasitic strategies (LeishDrug)
Visceral leishmaniasis is caused by the protozoan parasites Leishmania donovani and Leishmania infantum and is a potentially fatal disease in endemic areas around the world. During the infectious cycle, Leishmania alternate between the insect […]
2020Dynamic imaging reveals surface exposure of virulent Leishmania amastigotes during pyroptosis of infected macrophages., J Cell Sci 2020 Jun; 134(5): .
2020Leishmania amazonensis Subverts the Transcription Factor Landscape in Dendritic Cells to Avoid Inflammasome Activation and Stall Maturation, Front Immunol . 2020 Jun 9;11:1098.
2020Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response., Cell Rep 2020 Feb; 30(6): 1870-1882.e4.